Greulich T, et al. - In this post hoc analysis of the CRYSTAL study, which was a 12-week, prospective, multicenter, randomized, open-label study conducted in clinical practice settings, researchers determined the effect of a direct switch to once-daily indacaterol/glycopyrronium 110/50 µg (IND/GLY) from previous monotherapy with a long-acting β₂-agonist (LABA) or long-acting muscarinic antagonist (LAMA) or with an LABA and an inhaled corticosteroid (LABA + ICS) on reducing clinically important deterioration (CID). In real-life clinical practice, direct switch from LABA + ICS or LABA or LAMA to IND/GLY in moderate COPD patients resulted in attenuation in the risk of a CID.